Stockscreener 앱 받기
101.74
0.24%
0.24
시간 외 거래:
101.67
-0.07
-0.07%
전일 마감가:
$101.50
열려 있는:
$101.51
하루 거래량:
6.26M
Relative Volume:
1.24
시가총액:
$19.31B
수익:
$2.83B
순이익/손실:
$-1.02B
주가수익비율:
-18.46
EPS:
-5.51
순현금흐름:
$194.14M
1주 성능:
+0.77%
1개월 성능:
+51.78%
6개월 성능:
+90.10%
1년 성능:
+66.11%
1일 변동 폭
$101.30
$101.74
1주일 범위
$101.12
$101.95
52주 변동 폭
$38.81
$101.95
이그젝트 사이 Stock (EXAS) Company Profile
명칭
Exact Sciences Corp
전화
608-284-5700
주소
5505 ENDEAVOR LANE, MADISON, WI
EXAS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
101.74 | 19.26B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
575.91 | 215.01B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
228.53 | 159.87B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
700.55 | 56.23B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
140.60 | 39.54B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
223.63 | 37.85B | 15.90B | 1.28B | 2.21B | 7.2842 |
이그젝트 사이 Stock (EXAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-01-02 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-10-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-08-02 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-05-10 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2023-05-05 | 개시 | UBS | Neutral |
| 2023-03-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-02-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2021-11-03 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | 재확인 | BTIG Research | Buy |
| 2021-07-29 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-29 | 재확인 | Oppenheimer | Outperform |
| 2021-07-29 | 재확인 | Stifel | Buy |
| 2021-06-15 | 개시 | Raymond James | Strong Buy |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Equal Weight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-29 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-04-02 | 개시 | Evercore ISI | Outperform |
| 2020-01-10 | 재개 | BTIG Research | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Dougherty & Company | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-10-17 | 재확인 | BofA/Merrill | Buy |
| 2019-10-01 | 재개 | Craig Hallum | Buy |
| 2019-09-26 | 개시 | Oppenheimer | Outperform |
| 2019-02-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-09 | 개시 | UBS | Buy |
| 2018-09-05 | 재개 | The Benchmark Company | Hold |
| 2018-08-13 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-01-29 | 개시 | Goldman | Neutral |
| 2018-01-08 | 재확인 | The Benchmark Company | Buy |
| 2017-11-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
모두보기
이그젝트 사이 주식(EXAS)의 최신 뉴스
Gastrointestinal Diagnostics (GI) Market to Reach $5.8 Billion by 2030 - GlobeNewswire Inc.
EXAS Quantitative Stock Analysis - Nasdaq
Why Exact Sciences Stock Surged Today - AOL.com
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS - The AI Journal
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect - Business Wire
Quantbot Technologies LP Invests $604,000 in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences stock reaches 52-week high at 101.89 USD By Investing.com - Investing.com South Africa
Exact Sciences stock reaches 52-week high at 101.89 USD - Investing.com
1 Healthcare Stock for Long-Term Investors and 2 We Avoid - Finviz
Exact Sciences Showcases Breadth of Early Detection and Treatmen - GuruFocus
Peninsula company rides blank check to Wall Street after raising more than $1 billion as a startup - The Business Journals
Baird Financial Group Inc. Sells 30,218 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Assessing Exact Sciences After 77.5% YTD Surge and Abbott Deal Outlook - Yahoo Finance
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal? - Benzinga
Cancer detection firm Freenome to go public via $330 million SPAC deal - statnews.com
Cancer blood test maker Freenome going public with $330M SPAC - BioWorld MedTech
Assessing Abbott After 10.5% Gains and DCF PE Signals Amid Exact Sciences Deal Talk - simplywall.st
Has Exact Sciences Rally of Over 50% Left Room for Further Upside? - simplywall.st
OMERS ADMINISTRATION Corp Sells 113,387 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Published on: 2025-12-04 02:35:05 - Newser
Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report? - Yahoo Finance
Schroder Investment Management Group Raises Stock Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover - MSN
Exact Sciences (NASDAQ:EXAS) Sees Large Volume IncreaseHere's Why - MarketBeat
Top 2 Health Care Stocks You May Want To Dump This Month - Benzinga
Why Exact Sciences Corporation (EXK) stock gets analyst attentionCEO Change & Momentum Based Trading Signals - Newser
Mackenzie Financial Corp Has $151.76 Million Stock Position in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now - ts2.tech
Stifel downgrades Exact Sciences stock rating to Hold following Abbott acquisition news - Investing.com
UBS Reaffirms Buy Rating on Abbott Laboratories (ABT) Amid Exact Sciences Acquisition - Insider Monkey
Aug EndMonth: How Exact Sciences Corporation stock performs after earningsJuly 2025 Final Week & Reliable Entry Point Trade Alerts - BỘ NỘI VỤ
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the MergerEXAS, SEE, CDTX, and MRSN - The Malaysian Reserve
Exact Sciences Corporation $EXAS Shares Acquired by Magnetar Financial LLC - MarketBeat
Here Are Tuesday's Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, ServiceNow and More - 24/7 Wall St.
Exact Sciences (EXAS): Assessing Valuation After a 56% One-Month Rally - Yahoo Finance
Roche collaboration to accelerate Freenome’s blood-based cancer screening - Mugglehead Magazine
This Coinbase Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, ServiceNow and More - AOL.com
Exact Sciences (EXAS) Downgraded by Canaccord Genuity, PT Raised to $105 | EXAS Stock News - GuruFocus
Champlain Investment Partners LLC Has $134.44 Million Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Canaccord Genuity downgrades Exact Sciences stock to Hold after Abbott deal - Investing.com
Halper Sadeh LLC Encourages GDOT, BLFY, EXAS Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Exact Sciences stock rating downgraded to Hold by TD Cowen following Abbott deal - Investing.com
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium - Business Wire
UBS raises Exact Sciences stock price target to $105 on Abbott deal - Investing.com
Abbott is buying Exact Sciences. Here’s why - Modern Healthcare
Exact Sciences (EXAS) Downgraded to Hold by Benchmark Analyst | - GuruFocus
Here are Monday’s Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More - MSN
Exact Sciences (EXAS) Receives Downgrade from Jefferies Amidst P - GuruFocus
Here are Monday's Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More - 24/7 Wall St.
This Argenx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
이그젝트 사이 (EXAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.04%
0.32%
자본화:
|
볼륨(24시간):